Most Popular
-
1
Ador claims exclusive contracts with NewJeans still valid
-
2
Heavy, wet snow to fall more often this winter
-
3
SNU professors join growing movement calling for Yoon's resignation
-
4
Presidential office criticizes opposition-led state auditor, prosecutor impeachment motions
-
5
N. Korea launches 32nd wave of trash balloons, anti-S. Korea leaflets
-
6
‘NewJeans are no longer under Ador,’ says legal expert
-
7
[From the Scene] At this Starbucks, you need ID: Franchise opens store with view of North Korea
![[From the Scene] At this Starbucks, you need ID: Franchise opens store with view of North Korea](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/29/20241129050068_0.jpg&u=)
-
8
NewJeans leave for Japan shows day after unilaterally terminating contract with Ador
-
9
Will Min Hee-jin reunite with NewJeans?
-
10
Son Heung-min scores penalty in Europa League draw vs. Roma
![[From the Scene] At this Starbucks, you need ID: Franchise opens store with view of North Korea](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/29/20241129050068_0.jpg&u=)
Samsung Biologics’ 3rd plant gets business continuity certificate
By Lim Jeong-yeoPublished : May 19, 2020 - 15:27
Samsung Biologics, the world’s largest contract development and contract manufacturing organization for biologics drugs, said Tuesday that its third plant complies with international standards for business continuity management systems.
The plant is certified for compliance with ISO22301, a global standard set by the British Standard Institution, meaning the company’s business operations would experience minimal disruptions in the event of an accident or natural disaster.
Samsung Biologics had already acquired ISO22301 certification in April 2018 for individual features of its first and second plants. The additional accreditation covers its third plant, which began commercial operation in October 2018, as well as its bio-safety testing service lab and its small contract manufacturing organization manufacturing line.
Samsung Biologics’ third plant is the world’s largest single plant that has the throughput of 180,000 liters of biologics drug. It is equipped with N-1 perfusion technology, which can dramatically expedite the production rate.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
The plant is certified for compliance with ISO22301, a global standard set by the British Standard Institution, meaning the company’s business operations would experience minimal disruptions in the event of an accident or natural disaster.
Samsung Biologics had already acquired ISO22301 certification in April 2018 for individual features of its first and second plants. The additional accreditation covers its third plant, which began commercial operation in October 2018, as well as its bio-safety testing service lab and its small contract manufacturing organization manufacturing line.
Samsung Biologics’ third plant is the world’s largest single plant that has the throughput of 180,000 liters of biologics drug. It is equipped with N-1 perfusion technology, which can dramatically expedite the production rate.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
